RPG Life Sciences plans ₹500 crore acquisition push
In short
RPG Life Sciences plans to spend ₹500 crore on another acquisition within the next 12 months. It also wants 25% yearly growth in its API business over the next five years.
This matters because the company is signaling expansion and more deal activity. The report does not say which business it may buy or how it will fund the purchase.
What the reporting says
RPG Life Sciences plans to deploy ₹500 crore for another acquisition within 12 months, according to a Business Standard summary. The drugmaker also aims for 25% annual growth in its API business over the next five years, indicating a growth-and-expansion strategy. The reporting does not name the target, the financing mix, or whether a deal is already underway.
Why it matters
RPG Life Sciences plans to use ₹500 crore for another acquisition within 12 months, while targeting 25% annual growth in its API business over five years. The publisher summary frames this as an expansion plan for the drugmaker. The reporting does not name the target, explain the financing details, or confirm whether any acquisition process has begun.